FDA Issues 5-Point Action Plan For Artificial Intelligence/Machine Learning-Based SaMD
A new guidance document and a promise to hold a public workshop are just two commitments made by the US agency in a 12 January action plan aimed at AI/ML-based software as a medical device.
You may also be interested in...
Harmonization, Patient Trust Among Challenges In Regulating AI Devices
A panel of regulators and industry experts offered a variety of perspectives on artificial intelligence in medical devices and other digital health technology during the MedTech Conference in Boston.
FDA’s Digital Health Guru Stepping Away From Agency
Bakul Patel, who announced on 30 April that he will be moving on from the US FDA, leaves behind a legacy of innovation.
FDA Panel Meeting To Focus On AI/ML Device Labeling, Transparency
The US agency will host an October public workshop to get stakeholder input in developing a much-anticipated artificial intelligence/machine learning draft guidance.